Author

Mario Lopez-Prieto

Spanish National Cancer Research Centre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Alicia G. Serrano· 1 shared Belén Navarro‐GonzáleziD· 1 shared Carlota Cardona· 1 shared Daniela Hühn· 1 shared Eduardo ZarzuelaiD· 1 shared Elena Jiménez‐OrtegaiD· 1 shared Gema López-PernasiD· 1 shared Joaquı́n PastoriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alicia G. Serrano

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The tyrosine kinase inhibitor GNF-7 targets senescent cells through allosteric activation of GCN2.

Gema López-Pernas, Matilde Murga, Wareed Ahmed, Maria Häggblad, Elena Jiménez‐Ortega, Alicia G. Serrano, Carlota Cardona, Mario Lopez-Prieto, Samuele Fisicaro, Jorge Mota‐Pino, Belén Navarro‐González, Eduardo Zarzuela, Marta Elena Antón, Louise Lidemalm, Sonia Martinez, , Óscar Fernández-Capetillo

This study identifies GNF-7 as a senolytic drug that activates GCN2 to kill senescent cells, showing synergy with CDK4/6 inhibitors in preclinical models.

bioRxiv · Aug 29, 2025 · PreprintCancer Biology